Ayşe Melda Payaslıoğlu

Ayşe Melda Payaslıoğlu

Auto-generated profile, based on publicly available information

Ayşe Melda Payaslıoğlu

Bursa Uludağ Üniversitesi Tıp Fakültesi, Mikrobiyoloji Anabilim Dalı, Bursa, Türkiye

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Turkish Journal of Parasitology
Verified
Journal Article
Closed access
OAOktay Alver
Oktay Alver
APAyşe Melda Payaslıoğlu
Ayşe Melda Payaslıoğlu
CÖCüneyt Özakın
Cüneyt Özakın
SESema Esen
Sema Esen
This study aimed to retrospectively examine the indirect haemagglutination (IHA) test results of patients suspected of cystic echinococcosis (CE) and admitted to Bursa Uludağ University Health Practice and Research Center Hospital. Serum samples in the serology laboratory of our hospital were evaluated using the commercial Cellognost® echinococcosis IHA (Siemens Healthcare Diagnostics, Marburg, Germany) test based on the manufacturer's recommendations. In the IHA test, ≥1:64 serum titres were accepted as positive. Seropositivity was determined in 213 (19.9%) of 1.072 patients suspected of having CE by the IHA method. Of the patients with seropositivity, 120 (56.3%) were female and 93 (43.7%) were male. The highest positivity rate in both sexes was found in patients aged 20-29 years (22.5% in women; 14.1% in men). The results indicate that CE maintains its importance as a public health problem in Bursa as in Turkey.

1 December 2021 in Turkish Journal of Parasitology
Verified
Journal Article
Closed access
OAOktay Alver
Oktay Alver
APAyşe Melda Payaslıoğlu
Ayşe Melda Payaslıoğlu
ISIMRAN SAGLIK
IMRAN SAGLIK
This study aimed to retrospectively investigate Toxoplasma gondii IgG and IgM distribution and IgG avidity in serum samples with suspected toxoplasmosis in the medical microbiology serology laboratory of Faculty of Medicine Hospital at Bursa Uludağ University over a 24-month period (January 2016 to December 2018). An enzyme-linked fluorescent assay using the VIDAS automated analyzer (BioMérieux, France) was used to determine T. gondii IgM antibodies, T. gondii IgG antibodies, and T. gondii IgG avidity. The T. gondii IgM antibody positivity was found to be 1.7% (101/6104), whereas the T. gondii IgG antibody positivity was 37.9% (1.149/3024). The seropositivity of T. gondii IgG was 31.5% in women belonging to the childbearing age group. In this group, T. gondii IgG high and low avidity rates were 70.1% (134/191) and 15.2% (29/191), respectively. Screening and diagnosis of toxoplasma serology in women of childbearing age is important. The results of this study may be useful for designing optimal control and preventive measures against T. gondii infection.

24 September 2022 in Polish Journal of Microbiology
Verified
Journal Article
Open access
PDF file
NTNazmiye Ülkü Tüzemen
Nazmiye Ülkü Tüzemen
MPMelda Payaslioğlu
Melda Payaslioğlu
CÖCüneyt Özakın
Cüneyt Özakın
BEBeyza Ener
Beyza Ener
EAEMİN HALİS Akalin
EMİN HALİS Akalin
This study aims to investigate trends in bloodstream infections and their antimicrobial susceptibility profiles over 12 years in our hospital. This retrospective study was carried out in the Bursa Uludag University Hospital, Turkey, during 2008–2019. Blood cultures from patients were performed using BACTEC System. Isolates were identified with Phoenix System until 2018 and “matrix-assisted laser desorption ionization time-of-flight mass spectrometry” (MALDI-TOF MS) in 2019. Antibiotic susceptibility testing was performed with Phoenix System. Patient data came from the BD EpiCenter™ data management system. Escherichia coli was found to be the most common Gram-negative (11.6%), and coagulase-negative staphylococci were the most common Gram-positive (10.1%) monomicrobial growth. Overall, there was a significant increase in rates of extended-spectrum β-lactamase positive E. coli (p = 0.014) and Klebsiella pneumonia (p < 0.001), carbapenem-resistant E. coli (p < 0.001), and K. pneumoniae (p < 0.001) and colistin-resistant K. pneumoniae (p < 0.001) and Acinetobacter baumannii (p < 0.001) over 12 years. Carbapenem and colistin resistance has increased dramatically in recent years. We believe that regular monitoring of the distribution of pathogens and antibiotic susceptibility profiles, especially in intensive care units, can contribute to evidence for the increase in resistant microorganisms and help prevent their spread with antimicrobial stewardship and infection control policies.

1 September 2019 in Turkish Journal of Parasitology
Verified
Journal Article
Closed access
OAOktay Alver
Oktay Alver
MPMelda Payaslıoğlu
Melda Payaslıoğlu
BEBeyza Ener
Beyza Ener
The aim of this study is to investigate the distribution of anti-Toxoplasma gondii immunoglobulin G (IgG) and immünoglobulin M (IgM) antibodies in patients with suspected toxoplasmosis admitted to the Practice and Research Center of Health of the Medical Faculty of Uludağ University. The blood samples examined for the presence of anti-T. gondii IgG antibody and anti-T. gondii IgM antibody by an enzyme linked fluorescent assay test, anti-T. gondii IgG avidity value was evaluated by VIDAS (BioMérieux, France) kit. In our study, anti-T. gondii IgG seropositivity in 3311 (30.7%) of 10.603 cases and anti-T. gondii IgM seropositivity in 1423 (9.7%) of 14.618 cases were detected. Seropositivity of anti-T. gondii IgG was 37.5% in women of childbearing age group. The avidity value was high in 56.1% (n=156) and low in 28.9% (n=80) of childbearing age group women with positive anti-T. gondii IgG and anti-T. gondii IgM test. Especially in regions where seroprevalence is high, we think that pregnant women and women of childbearing age should be investigated in terms of T. gondii antibodies.

4 August 2021 in Turkish Journal of Parasitology
Verified
Journal Article
Closed access
OAOktay Alver
Oktay Alver
APAyşe Melda Payaslıoğlu
Ayşe Melda Payaslıoğlu
CÖCüneyt Özakın
Cüneyt Özakın
SESema Esen
Sema Esen

24 January 2023 in Journal of Molecular Virology and Immunology
Verified
Journal Article
Closed access
ISIMRAN SAGLIK
IMRAN SAGLIK
MPMelda Payaslıoğlu
Melda Payaslıoğlu
RAReyhan Başkılıç Aydın
Reyhan Başkılıç Aydın
BEBeyza Ener
Beyza Ener
HAHARUN AGCA
HARUN AGCA
EAEMİN HALİS Akalin
EMİN HALİS Akalin
Türkiye's first SARS-CoV-2 vaccination campaign started with an inactivated vaccine (Sinovac Life Sciences Co., Ltd., Beijing, China) mid-January 2021 for healthcare workers. The second dose was administered at an interval of 21 days-one month. As of July 2021 (4-4.5 months after the second dose), the Republic of Türkiye Ministry of Health suggested the third vaccination dose for healthcare workers and people over 50. The individuals could select between the choice of CoronaVac or an mRNA vaccine BNT162b2 (Pfizer‐BioNTech, Inc) for the third dose vaccination. Thus, a heterogeneous immunization emerged in society. This study is aimed to investigate the humoral response (IgG and IgM) after two doses of the SARS-CoV-2 vaccine and the possible effects of factors for this response, as well as to compare the third dose of homogeneous and heterogeneous vaccine administration. The study included 512 volunteers who are 21-65 years old that have been immunized against SARS-CoV-2 in at least two doses, working at Bursa Uludag University Faculty of Medicine Health Application and Research Center. The demographic characteristics of the participants (such as age, gender, and place of duty), background (presence of chronic disease, risky contact for SARS-CoV-2 transmission, and history of COVID-19 infection), and immunization characteristics were obtained with a questionnaire. Participants were divided into five main groups regarding the time elapsed months after the second dose and the type of vaccine administered (CoronaVac or BNT162b2). Group 1b (n=11); (blood samples were taken) one month after the second dose of BNT162b2 vaccine, group1c (n=12); one month after the second dose of CoronaVac, group 2 (n=9); two months after the second dose of CoronaVac vaccine, group 3 (n=27); three months after of CoronaVac vaccine, group 4 (n=418); four months after the second dose of CoronaVac vaccine and group 5 (n=35); five months after the second dose of CoronaVac vaccine. One month later, blood samples were taken from 52 participants in group 4 who received the third dose of the vaccine. In these participants, IgG levels were compared after two different third-dose vaccines [BNT162b2; group 4b (n=30) and CoronaVac; group 4c (n=22)]. SARS-CoV-2 IgM and IgG responses were evaluated by SARS-CoV-2 IgM (Abbott, USA) and IgG Quant II (Abbott, USA) kits on Architect i2000SR (Abbott, USA) autoanalyzer with a chemiluminescent based method at Bursa Uludag University Faculty of Medicine Medical Microbiology Laboratory. In this study, a high rate (>80%) of anti-S IgG seroconversion was observed in all groups given two doses of the SARS-CoV-2 vaccine. The median IgG levels in groups 1b, 1c, 2, 3, 4, and 5 were 4315.3 AU/mL (24-10337), 721.5 AU/mL (154-1430), 842.5 AU/mL (365-4447), 183.0 AU/mL (14-1635), 165.0 AU/mL (4-31796) and 110.0 AU/mL (28-8757), respectively. After CoronaVac vaccination with two doses, groups 3, 4, and 5 had low levels of anti-SARS-CoV-2 IgG compared to group 1c (p values: 0.034, 0.006, and 0.001, respectively). IgM positivity was between 12.5-33.5% in the participants whose blood samples were obtained at one, two, and three months after the vaccination and 3.2-4.3% in the participants after four and five months (p=0.001). The heterogeneous immunization [two doses of CoronaVac and one dose of BNT162b2: median 11084.5 AU/mL (2948-40000)] has provided higher SARS-CoV-2 IgG levels compared to homogeneous immunization [three doses of CoronaVac: median 1707.0 AU/mL (304-8322)] (p60) was the most critical negative factor in IgG levels (p=0.001). Unlike previous research, it was found that the presence of comorbidity and gender did not affect the vaccine response after four months. Having a high-risk contact history and working in high-risk areas (pandemic ward) did not affect the antibody response. Among the factors evaluated, the only factor affecting IgM positivity was the combination of vaccine and natural immunity. Decreased levels of anti-S IgG antibody three months after the CoronaVac vaccine may affect the protection, especially in advanced age groups. Although this situation creates a guide for the planning of booster doses, the neutralizing antibody and T-cell response are important for protection.